Severe Combined Immunodeficiency (SCID) is a rare but extremely serious genetic disorder in which a child is born with a profoundly impaired immune system.

Understanding SCID: A Life-Threatening Immune Condition

Patients with SCID have defects in both T-cell and B-cell function, leaving them vulnerable to recurrent infections, failure to thrive, and organ complications. Without appropriate treatment, SCID is often fatal within the first year of life.

SCID affects approximately 1 in 50,000 to 100,000 births worldwide, although incidence varies by region. The condition may be caused by various genetic mutations, including IL2RG (X-linked SCID), ADA deficiency, JAK3 mutations, RAG1/2 mutations, and others. These mutations prevent the immune system from developing properly.

Early symptoms include:

• Severe viral, fungal, or bacterial infections
• Chronic diarrhea
• Persistent oral thrush
• Pneumonia
• Inability to gain weight or grow
• Infections that do not respond to usual treatment

Infants with SCID require urgent medical evaluation and protective isolation to prevent life-threatening infection.

Current Standard Treatments: Bone Marrow Transplant & Gene Therapy

Historically, the most successful treatment for SCID is hematopoietic stem cell transplantation (HSCT) from a matched sibling donor. Transplanted bone marrow stem cells can rebuild the child’s immune system.

However:

• Only 20–25% of patients have a matched sibling donor
• Transplant complications may include graft-versus-host disease (GVHD)
• Conditioning chemotherapy may be toxic to infants

Recently, gene therapy has shown major promise, especially for patients with ADA-SCID or X-linked SCID. Correcting the patient’s own faulty immune cells helps restore functional immunity without needing a donor. Several gene therapy clinical trials have reported survival rates of 90% or higher

Although HSCT and gene therapy remain the gold standards, regenerative medicine using UC-MSC therapy is emerging as an adjunctive treatment to reduce complications, support immune stability, and improve long-term tissue repair.

How UC-MSC Stem Cell Therapy May Support SCID Patients (TISTR/วว GMP)

Mesenchymal stem cells (MSCs) do not replace bone marrow transplantation, but research shows they play a significant supportive role in immune regulation, inflammation reduction, and improved transplant outcomes.

All UC-MSCs used at EDNA Wellness are sourced from TISTR GMP–certified laboratories, ensuring safety, sterility, and regulatory quality.

Key Biological Mechanisms of MSCs in SCID

Immune Modulation

MSCs downregulate overactive immune responses and reduce inflammatory cytokines such as TNF-α, IL-6, IL-1β, and IFN-γ
This is especially helpful for:

• Post-transplant complications
• Tissue inflammation
• GVHD risk
• Chronic infections that create excessive inflammation

Tissue Repair

SCID patients often experience lung, gut, or liver damage due to recurrent infections.
MSCs:

• Promote angiogenesis
• Reduce fibrosis
• Support epithelial repair
• Enhance organ healing

Enhancing Bone Marrow Transplant Outcomes

MSCs have been used clinically to help:

• Reduce GVHD after HSCT
• Support bone marrow engraftment
• Improve survival in complicated SCID transplants

Anti-inflammatory Cytokine Secretion

UC-MSCs release IL-10, TGF-β, and prostaglandin E2—potent regulators that calm hyperinflammatory states common in SCID complications.

Why UC-MSC Therapy Is Considered an Adjunct, Not a Replacement

UC-MSC therapy does not cure SCID.
Instead, it is considered medically valuable in specific circumstances:

• When patients experience severe inflammation
• When tissue damage persists post-infection
• When HSCT causes complications
• When immune dysregulation remains after treatment
• When supportive regeneration is needed

Multiple studies show MSCs help stabilize immune recovery and reduce transplant-related toxicity.

At EDNA Wellness, UC-MSC therapy is offered only when medically appropriate, with full clinical evaluation and adherence to Thai regenerative-medicine guidelines.

What a Regenerative Program May Include

Because SCID is complex, treatment must be fully individualized.

A regenerative supportive plan at EDNA Wellness may include:

• UC-MSC therapy (TISTR/วว GMP)
• Nutritional immune support
• Antioxidant therapy for inflammation
• NAD⁺ therapy for mitochondrial repair (Thai FDA–approved formulations)
• Organ function monitoring
• Collaboration with immunologists or pediatric specialists

Any infant or child with suspected SCID should remain under specialist care. EDNA Wellness focuses on adjunctive regenerative support for stable patients, not acute care.

Safety Considerations

UC-MSC therapy has a strong safety profile when produced under GMP conditions. Reported side effects are generally mild:

• Temporary fever
• Injection-site soreness
• Transient fatigue

MSCs are immune-privileged, meaning they do not trigger rejection in most patients.

However, SCID patients are medically fragile. MSC therapy must be:

• Clinically justified
• Supervised by experienced physicians
• Given only with high-quality, TISTR/วว–verified products
• Combined with careful immunological monitoring

EDNA Wellness strictly follows medical safety protocols.

SCID is a severe immunodeficiency requiring urgent diagnosis and specialized treatment. While bone marrow transplant and gene therapy remain the gold standards, UC-MSC regenerative therapy provides additional benefits, helping reduce inflammation, support organ repair, and improve transplant outcomes

About EDNA Wellness

EDNA Wellness is a private clinic specializing in Stem Cell Therapy in Bangkok, Thailand for Neurology & Stroke as well as Bones & Joints. Beyond rehabilitation, we also provide aesthetic and wellness treatments to support your full-body vitality. All delivered with expert care and compassion

For more information or inquiries, contact us via

LINE @ednawellness

WhatsApp +66 (0) 64 505 5599

www.ednawellness.com

References

• Chen, J., et al. (2021). Mesenchymal stem cell therapy for immune disorders. Frontiers in Immunology, 12, 718.
• Kwan, A., et al. (2014). Newborn screening for SCID — A public health perspective. Journal of Allergy and Clinical Immunology, 133(3), 597–603.
• Kode, J. A., Mukherjee, S., Joglekar, M. V., & Hardikar, A. A. (2009). Mesenchymal stem cells: Immunobiology and role in immune-mediated disorders. Cytotherapy, 11(4), 377–392.
• Le Blanc, K., et al. (2012). Mesenchymal stromal cells to treat graft-versus-host disease. The Lancet, 371(9624), 1579–1586.
• Liu, S., et al. (2021). Mesenchymal stem cells improve outcomes in transplantation complications. Stem Cell Research & Therapy, 12, 162.
• Mamcarz, E., et al. (2019). Gene therapy for ADA-SCID: Long-term results. New England Journal of Medicine, 380(5), 451–463.
• Squillaro, T., Peluso, G., & Galderisi, U. (2016). Clinical trials with mesenchymal stem cells: An update. Cell Transplantation, 25, 829–848.
• Wang, L., et al. (2020). Mesenchymal stem cells in immune modulation. Stem Cell Research & Therapy, 11, 1–13.